New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 7, 2014
08:33 EDTABT, DXCMDexCom reports settlement and license agreement with Abbott Diabetes Care
On July 2, DexCom (DXCM) entered into a Settlement and License Agreement with Abbott Diabetes Care (ABT). The Settlement Agreement was entered into in full settlement of all pending patent infringement legal proceedings brought by Abbott against the Company. The Settlement Agreement obligates the parties to promptly file a joint stipulation of dismissal of all pending legal proceedings.The Settlement Agreement does not obligate the company to pay any royalties or any other form of financial compensation. The Settlement Agreement provides for a royalty-free, worldwide, non-exclusive, non-sublicensable cross-license of certain patents. The company receives a limited license from Abbott to the patents that Abbott has alleged that the company infringed. The company grants to Abbott a limited license of certain patents with an actual filing date prior to January 1, 2005. In addition, each party agrees not to (1) sue the other party for patent infringement based on certain of their respective continuous glucose monitoring products, and (2) challenge any patent or patent application held by the other party, subject to certain limited exceptions, in each case, until March 31, 2021. The cross-license and mutual covenant not to sue granted to each party do not apply to the type of sensor technology used by the other party. Comments taken from an 8-K filing.
News For DXCM;ABT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 30, 2015
17:00 EDTDXCMTandem Diabetes enters development agreements with DexCom
Subscribe for More Information
11:02 EDTABTAbbott to purchase Tendyne Holdings, Cephea Valve Technologies
Subscribe for More Information
July 22, 2015
10:06 EDTABTAbbott CEO says supportive of Mylan pursuit of Perrigo
Subscribe for More Information
09:33 EDTABTAbbott sees Q3 Diagnostics sales up mid single digits on operational basis
Subscribe for More Information
09:30 EDTABTAbbott CEO says 'pretty alligned' with Mylan so far
09:15 EDTABTAbbott sees FY15 reported sales growth to be in low single digits
Subscribe for More Information
09:15 EDTABTAbbott sees Q3 EPS 52c-54c, consensus 55c
Sees Q3 impact from foreign exchange to be "somewhat above" 9% based on current exchange rates, resulting in reported sales growth in the low single digits, consensus $5.19B. Guidance from Q2 earnings call.
09:07 EDTABTOn The Fly: Pre-market Movers
Subscribe for More Information
09:07 EDTABTAbbott says foreign exchange impacting results more than expected in January
Subscribe for More Information
07:49 EDTABTAbbott reports Q2 Nutrition sales $1.72B, Diagnostics sales $1.18B
Subscribe for More Information
07:48 EDTABTAbbott backs FY15 adjusted EPS $2.10-$2.20, consensus $2.16
Abbott forecasts net specified items related to continuing operations for the full year 2015 of approximately 60c per share.
07:47 EDTABTAbbott reports Q2 adjusted EPS 52c, consensus 50c
Subscribe for More Information
July 21, 2015
15:02 EDTABTNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's open, with earnings consensus, include Coca-Cola (KO), consensus 60c... Boeing (BA), consensus $1.42... Abbott Laboratories (ABT), consensus 50c... Thermo Fisher Scientific (TMO), consensus $1.78... EMC (EMC), consensus 41c... Illinois Tool Works (ITW), consensus $1.28... St. Jude Medical (STJ), consensus $1.00... Northern Trust (NTRS), consensus 96c... Check Point Software (CHKP), consensus 95c... Polaris Industries (PII), consensus $1.58... Interpublic Group (IPG), consensus 27c... New York Community Bancorp (NYCB), consensus 26c... B/E Aerospace (BEAV), consensus 76c... Owens Corning (OC), consensus 54c... Knight Transportation (KNX), consensus 37c.
July 20, 2015
09:02 EDTABTAbbott receives FDA approval and launches iDesign Advanced WaveScan system
Subscribe for More Information
08:38 EDTABTAnalyst predicts Zoetis merges with Bayer unit, not Valeant
Zoetis (ZTS) in recent months has been the subject of takeover speculation, possibly for Valeant (VRX), but a Jefferies analyst told investors today in a research note that he views a deal with a unit of healthcare giant Bayer (BAYRY) as "highly likely" for the animal medicine company. BACKGROUND: Bill Ackman of Pershing Square, who owns stakes in both Zoetis and Valeant, said in early May while speaking on CNBC that Zoetis is a "great” business on a standalone basis, but he also spoke of the company's strategic value. Ackman added, however, that he was "not sure" that Valeant was the best acquirer of Zoetis. Subsequently, in late June, The Wall Street Journal reported that Valeant made a preliminary approach regarding a potential deal to buy Zoetis. CNBC's David Faber said the next day, citing his own sources, that Valeant reached out to Zoetis as a courtesy to common shareholder Ackman and was unlikely to pursue an acquisition of the company, though he cautioned then Valeant could change its approach and pursue a deal. BAYER: Jefferies analyst Jeffrey Holford said in a note today that he views a tie-up between Zoetis and Bayer's Animal Health business in 2016 as "highly likely." He sees Mylan's (MYL) acquisition of Abbott's (ABT) non‑U.S. developed markets specialty and branded generics business as a potential proxy for how a transaction could be structured, adding that such a "spinversion" could achieve up to 36% long-term earnings accretion for Zoetis. Holford reiterated a Buy rating on Zoetis with a $60 price target, while downgrading Bayer to Hold, citing valuation following the recent outperformance of its shares. IDEXX: While being discussed as a target, some analysts have also opined on companies that Zoetis could pursue as a buyer. On June 29, Canaccord said that in investor meetings with IDEXX (IDXX) executives declined to comment on Zoetis' potential interest in scaling up its animal health diagnostics business. Canaccord added that it thought Zoetis could make a bid for IDEXX. The firm reiterated its Buy rating and $80 price target on IDEXX shares at that time. PRICE ACTION: Since June 25, the day the Journal first reported on Valeant's preliminary takeover approach to Zoetis, the animal health company's shares have dropped nearly 4%. Zoetis closed down 20c to $47.80 on Friday.
07:33 EDTABTInternational AIDS Society to hold a conference
Subscribe for More Information
07:30 EDTABTZoetis 'highly likely' to merge with Bayer unit in 2016, says Jefferies
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use